NASDAQ:AADI Aadi Bioscience (AADI) Stock Price, News & Analysis $4.16 +0.05 (+1.22%) As of 06/26/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About Aadi Bioscience Stock (NASDAQ:AADI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aadi Bioscience alerts:Sign Up Key Stats Today's Range$4.08▼$4.2650-Day Range$3.80▼$5.1052-Week Range$1.21▼$3.81Volume3.96 million shsAverage Volume261,100 shsMarket Capitalization$102.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways. The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). Fimepinostat is currently being evaluated in multiple Phase 1/2 clinical trials in patients with relapsed or refractory non-Hodgkin lymphomas, pediatric high-risk neuroblastoma and other genomically defined malignancies. Aadi Bioscience has established collaborations with leading academic centers in the United States and Europe to advance the clinical development of fimepinostat and explore combination regimens with other targeted therapies. In addition to its lead program, Aadi Bioscience is advancing a discovery pipeline aimed at identifying novel targets in rare and aggressive cancers with unmet medical needs. The company’s integrated approach combines biomarker-driven patient selection with translational research capabilities to streamline clinical development and enhance the probability of success. Aadi’s team includes seasoned executives and oncology researchers, led by President and Chief Executive Officer Stephen J. Waintraub, who bring extensive experience in drug development, regulatory affairs and commercialization in the oncology sector.AI Generated. May Contain Errors. Read More Receive AADI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AADI Stock News HeadlinesPancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsightOctober 13, 2025 | finance.yahoo.comWhitehawk Therapeutics May 2025 slides: Pivoting to ADC development with three candidatesMay 15, 2025 | uk.investing.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 27 at 1:00 AM | Porter & Company (Ad)Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightMay 14, 2025 | finance.yahoo.comMarginal Benefits in High-Risk Ovarian Cancer With Addition of Bevacizumab to ChemoMay 13, 2025 | msn.comFYARRO Sets New Standard in Rare Oncology Market with Strong Growth Prospects | DelveInsightApril 17, 2025 | finance.yahoo.comWhitehawk Therapeutics files to sell 41.67M shares of common stock for holdersApril 2, 2025 | markets.businessinsider.comWhitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken PharmaceuticalsMarch 26, 2025 | finance.yahoo.comSee More Headlines AADI Stock Analysis - Frequently Asked Questions How have AADI shares performed this year? Aadi Bioscience's stock was trading at $2.47 at the beginning of the year. Since then, AADI stock has increased by 68.4% and is now trading at $4.16. How were Aadi Bioscience's earnings last quarter? Aadi Bioscience, Inc. (NASDAQ:AADI) issued its earnings results on Tuesday, March, 18th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.37. The firm had revenue of $7.24 million for the quarter, compared to analysts' expectations of $7.45 million. Aadi Bioscience had a negative trailing twelve-month return on equity of 71.87% and a negative net margin of 246.06%. Read the conference call transcript. When did Aadi Bioscience's stock split? Aadi Bioscience shares reverse split before market open on Friday, August 27th 2021.The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Aadi Bioscience? Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aadi Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aadi Bioscience investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Moderna (MRNA), NVIDIA (NVDA) and Alphabet (GOOG). Company Calendar Last Earnings3/18/2025Today6/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AADI CIK1422142 Webaadibio.com Phone(424) 473-8055FaxN/AEmployees40Year Founded2011Profitability EPS (Trailing Twelve Months)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.76 million Net Margins-246.06% Pretax Margin-246.06% Return on Equity-71.87% Return on Assets-57.28% Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.54 Sales & Book Value Annual Sales$25.07 million Price / Sales4.10 Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.97Miscellaneous Outstanding Shares24,697,000Free Float15,485,000Market Cap$102.74 million OptionableNo Data Beta0.68 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:AADI) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aadi Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AADI Stock Alerts